Rapidly spreading wildfires have taken over the news headlines from the Los Angeles area, as I write this column. Dry weather and the Santa Ana winds joined forces to create an inferno there. Wildfires are just one emergency that the pulmonary fibrosis (PF) community must be prepared to…
Inhibiting the HIF2 protein — fully, hypoxia-inducible factor 2 — was found to ease scarring in a mouse model of lung injury and could be a promising therapeutic strategy for treating idiopathic pulmonary fibrosis (IPF), according to the results of new preclinical research. In the lab, a team of…
Each new year brings an influx of marketing about resolutions, hopes, and wishes. If you’re like me, your social media feed is flooded with related ad campaigns this month. A new year often sparks hope for positive changes regarding a person’s physical health, mental wellness, or finances. I don’t typically…
Do you make resolutions for the new year? A revealing joke on the subject has been around for years. In it, an entrepreneur opens and stocks a gym on New Year’s Day to support those who’ve made resolutions to exercise. After the first two weeks, though, the gym equipment is…
Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced idiopathic pulmonary fibrosis (IPF) in mice, according to a study identifying the enzyme as a potential therapeutic target for the condition. Experiments showed that FASN was elevated in lung scar…
The investigational therapy LYT-100 (deupirfenidone) significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF), outperforming the standard of care therapy Esbriet. PureTech Health’s treatment candidate also caused fewer gastrointestinal side effects in patients. That’s according to top-line data from the ongoing Phase…
The holidays have arrived, which reminds of those passenger-side mirrors that read, “Objects in mirror are closer than they appear.” It wasn’t too long ago that the holidays seemed far away, yet here they are. After I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2017, my health…
Trevi Therapeutics announced that its ongoing Phase 2b clinical trial testing Haduvio (nalbuphine extended-release tablets) in people with idiopathic pulmonary fibrosis (IPF) who have chronic cough has reached 75% of its targeted patient enrollment. The Phase 2b CORAL trial (NCT05964335) is still seeking to recruit a…
Good grief! When I hear this two-word phrase, I often associate it with the cartoon character Charlie Brown. Otherwise, the words “good” and “grief” seldom seem to belong together. What do you do with grief amid the holiday season? If you’ve been reading my columns for some time,…
The first patient has been dosed in a Phase 2b clinical trial of Endeavor Biomedicines’ investigational oral therapy ENV-101 (taladegib) in people with idiopathic pulmonary fibrosis (IPF). WHISTLE-PF (NCT06422884) seeks to enroll around 200 adults in 14 countries. The first patient was dosed in Australia. The study’s launch…
Get regular updates to your inbox.
